Veraxa Biotech AGNASDAQ: VRXA

VERAXA Biotech (NASDAQ: VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing

· Issued by Veraxa Biotech AG

Summary by 6ix AI

VERAXA Biotech, a developer of antibody-based cancer therapies, gave an update on October 7, 2026 on its strategy to use U.S. Food and Drug Administration (FDA)-aligned New Approach Methodologies (NAMs), alternative testing methods, across its preclinical research and development programs.

Key details

  • VERAXA says the approach could speed clinical advancement, reduce development costs and timelines and significantly reduce animal testing.
  • The company has built a panel of NAMs to characterize and de-risk its pipeline of BiTAC-based T cell engagers (antibodies that direct immune T cells against cancer cells), antibody-drug conjugates (antibodies carrying a drug) and bispecific antibody-drug conjugates.
  • VERAXA said its lead T cell engager and bispecific antibody-drug conjugate candidates were tested ex vivo (outside a living body) on a panel of 10 low-passage (grown through few generations) patient-derived xenograft models (tumours grown from patient tissue in mice) of non-small cell lung cancer.
  • VERAXA said the panel required about 10 mice in total, compared with an estimated 200 or more for comparable efficacy studies in live animals.
  • VERAXA says the combined BiTAC consistently induced potent T cell-mediated killing across the panel, which it says supports its dual-targeting approach.

6ix AI wrote this summary from the release below and checked it against the release.

On 6ix: 6ix.com/news/veraxa-biotech-nasdaq-vrxa-advances-fda-aligned-methods-to-reduce-animal-testing

Featured Image

Austin, Texas, United States, October 7th, 2026, NewsDirect

VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, provided an update on its strategy to implement U.S. Food and Drug Administration "FDA"-aligned New Approach Methodologies "NAMs" across its preclinical research and development programs. The company said the approach could accelerate clinical advancement, reduce development costs and timelines and significantly reduce animal testing. VERAXA has built a panel of NAMs to characterize and de-risk its pipeline of BiTAC-based T cell engagers, antibody-drug conjugates and bispecific antibody-drug conjugates.

VERAXA said its lead BiTAC-TCE and bsADC candidates were also evaluated using an ex vivo panel of 10 low-passage patient-derived xenograft models of non-small cell lung cancer. The panel required about 10 mice in total, compared with an estimated 200 or more for comparable in vivo efficacy studies. Across the panel, the combined BiTAC consistently induced potent T cell-mediated killing, supporting the company's dual-targeting approach and demonstrating how its NAM strategy can reduce animal use and preclinical cycle time without compromising clinical relevance.

To view the full press release, visit https://ibn.fm/9YRJw

About VERAXA Biotech AG

At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.

BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.IBN.ai

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer

The latest news and updates relating to VRXA are available in the company's newsroom at https://ibn.fm/VRXA

Corporate Communications

IBN Austin, Texas www.IBN.ai 512.354.7000 Office Editor@IBN.ai

Contact
IBNwww.InvestorBrandNetwork.comEditor@InvestorBrandNetwork.com

Veraxa Biotech AG on 6ix

Earlier from Veraxa Biotech

Later from Veraxa Biotech

All Veraxa Biotech news releases